Finasteride and dutasteride both belong to the class of 5-alpha reductase inhibitors, but they differ in potency and scope. Understanding these differences can help you make an informed decision, particularly if finasteride has not delivered the results you hoped for.
How They Differ Mechanistically
Finasteride inhibits only the type II isoform of 5-alpha reductase, reducing serum DHT by approximately 60–70%. Dutasteride inhibits both type I and type II isoforms, reducing DHT by approximately 90%. This more complete DHT suppression is why dutasteride is considered the more potent option.
What Does the Clinical Evidence Show?
Several head-to-head studies have been conducted:
- A 2006 randomised controlled trial found that dutasteride 0.5 mg produced significantly greater increases in hair count compared to finasteride 1 mg after 12 and 24 weeks
- A large phase III trial published in the Journal of the American Academy of Dermatology (2016) confirmed dutasteride was superior to finasteride for hair count and hair width after 24 weeks
- South Korea and Japan have licensed dutasteride for androgenetic alopecia based on this evidence, though no equivalent licence exists in the UK
UK Licensing and MHRA Status
In the UK, dutasteride (brand name Avodart) is licensed at 0.5 mg daily for benign prostatic hyperplasia only. The manufacturer has not sought an MHRA marketing authorisation for hair loss. This means the formal regulatory process for this indication has not been completed. Some private clinicians and online services in the UK prescribe dutasteride off-label for hair loss.
⚠ Off-label use: Because dutasteride lacks an MHRA licence for hair loss, prescribers take individual clinical responsibility when prescribing it for this purpose. Patients should receive clear informed consent about the off-label nature of the prescription and the longer drug half-life (approximately 5 weeks) compared to finasteride.
Side Effect Comparison
Both medications share a similar side effect profile, including potential effects on libido, erectile function, and ejaculation. Because dutasteride suppresses DHT more aggressively, some researchers suggest the risk may be marginally higher, though head-to-head studies have not found statistically significant differences in side effect rates.
A critical difference is the half-life: dutasteride has a half-life of approximately 5 weeks, compared to 6–8 hours for finasteride. This means dutasteride takes much longer to clear the body after stopping, which is an important consideration if side effects develop.
Who Should Consider Dutasteride?
Dutasteride is typically considered for men who have:
- Used finasteride for 12 months or more without satisfactory results
- Moderate to advanced hair loss requiring more aggressive DHT suppression
- Discussed the off-label nature and risks with a qualified prescriber
The Bottom Line
Finasteride remains the first-line treatment in the UK due to its licensing, shorter half-life, and extensive safety data. Dutasteride is a reasonable second-line option for non-responders, but should only be used under proper medical supervision from a registered prescriber.